Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Stoneridge remains a 'buy' despite near-term automotive sector headwinds and a 27.9% stock decline since reaffirmation. 2025 revenue and EBITDA guidance were revised downward, but multi-year contract wins—especially for MirrorEye—support optimism for outsized long-term growth. Current valuation is not exceptional versus peers, but if SRI achieves its 2026–2029 targets, shares could be extremely undervalued.

LOS ANGELES, Dec. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Firefly Aerospace Inc. (“Firefly” or “the Company”) (NASDAQ: FLY) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering (“IPO”) conducted on August 7, 2025, and/or between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period"), are encouraged to contact the firm before January 12, 2026.

ING Groep delivered robust Q3 results, maintaining strong profitability and capital generation amidst a stable eurozone outlook. ING's CET1 capital ratio stands at 13.4%, enabling a €1.1B share buyback and €500M dividend, with continued capital build expected. Dividend policy targets ~50% payout and ongoing buybacks, supporting rising EPS and yield; 2027 consensus implies a 5.4% yield at 9x earnings.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options

RADNOR, Pa. , Dec. 26, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of CoreWeave, Inc. (NASDAQ: CRWV) ("CoreWeave").

Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal of a phase 2 trial.

Rocket Pharmaceuticals is rated Buy with a $17 price target, reflecting a deep disconnect between intrinsic value and current valuation. RCKT's bullish thesis hinges on a high-probability LAD-1 approval in March 2026 and the pivotal Danon's disease trial resuming with an amended, safer protocol. Risk-adjusted DCF values Danon's and LAD-1 programs at ~$700M, far exceeding the current $151M EV, even under conservative or bear-case assumptions.

Buying low and selling high is a tried-and-true strategy for both buy-and-hold investors and active traders. When a stock is trading at or near its 52-week low, the stock price is trading at one of its lowest points of the year.